title: Valproic acid does not affect markers of human immunodeficiency virus disease progression.
abstract: Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.
authors.affiliation: Department of Neurosciences, University of California, San Diego, California, USA. bances@ucsd.edu
authors.forename: Beau M
authors.initials: BM
authors.lastname: Ances
authors.forename: Scott
authors.initials: S
authors.lastname: Letendre
authors.forename: Maria
authors.initials: M
authors.lastname: Buzzell
authors.forename: Jennifer
authors.initials: J
authors.lastname: Marquie-Beck
authors.forename: Deborah
authors.initials: D
authors.lastname: Lazaretto
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Marcotte
authors.forename: Igor
authors.initials: I
authors.lastname: Grant
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Ellis
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018450:Disease Progression; D005260:Female; D006678:HIV / Q000235:genetics / Q000302:isolation & purification; D015658:HIV Infections / Q000503:physiopathology*; D006801:Humans; D008297:Male; D014635:Valproic Acid / Q000494:pharmacology*; D019562:Viral Load
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers; D014635:Valproic Acid